BRAF V600E (Q21851559)

From Wikidata

Jump to navigation Jump to search

genetic variant

VAL600GLU
V600E
RS113488022
V640E
VAL640GLU

Language	Label	Description	Also known as
English	BRAF V600E	genetic variant	VAL600GLU V600E RS113488022 V640E VAL640GLU

Statements

missense mutation

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

human chromosome 7

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

140453136

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

140453136

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

positive therapeutic predictor for

Dabrafenib / Trametinib combination therapy

medical condition treated

determination method

CIViC evidence level B

CIViC 5-star trust rating

Vemurafenib / Gefitinib / Cetuximab combination therapy

medical condition treated

colorectal cancer

determination method

CIViC evidence level D

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1408

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Vemurafenib / Panitumumab combination therapy

medical condition treated

colorectal cancer

statement disputed by

Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1413

Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients

Vemurafenib / Panitumumab combination therapy

medical condition treated

colorectal cancer

determination method

CIViC evidence level C

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1589

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

Dabrafenib / Trametinib combination therapy

medical condition treated

non-small-cell lung carcinoma

determination method

CIViC evidence level A

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/3017

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

medical condition treated

colorectal cancer

determination method

CIViC evidence level D

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/99

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer

medical condition treated

determination method

CIViC evidence level C

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/757

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors

medical condition treated

determination method

CIViC evidence level B

CIViC 5-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1398

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

medical condition treated

colorectal cancer

statement disputed by

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1405

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

medical condition treated

determination method

CIViC evidence level A

CIViC 5-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1409

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

medical condition treated

papillary thyroid cancer

determination method

CIViC evidence level C

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1414

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib

medical condition treated

hairy cell leukemia

determination method

CIViC evidence level B

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1579

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

medical condition treated

papillary thyroid cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1591

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial

medical condition treated

multiple myeloma

determination method

CIViC evidence level C

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1698

Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

medical condition treated

multiple myeloma

determination method

CIViC evidence level C

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1699

Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

cobimetinib fumarate

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1141

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

vemurafenib / cobimetinib fumarate combination therapy

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1421

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

trametinib / vemurafenib / dabrafenib combination therapy

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

gastrointestinal neuroendocrine tumor

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1430

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy

Irinotecan / Vemurafenib / Cetuximab combination therapy

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1902

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation

Dabrafenib / Trametinib combination therapy

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/3758

Improved overall survival in melanoma with combined dabrafenib and trametinib

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5958

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5959

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5960

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

laryngeal squamous cell carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5962

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

Panitumumab / Dabrafenib / Trametinib combination therapy

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6123

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Panitumumab / Trametinib combination therapy

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal adenocarcinoma

statement disputed by

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6124

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Sorafenib / Panitumumab combination therapy

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/89

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

irinotecan / Panitumumab / vemurafenib combination therapy

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

cholangiocarcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5906

Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

statement disputed by

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1406

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1410

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Dabrafenib / Trametinib combination therapy

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6940

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Capecitabine / Vemurafenib / Bevacizumab combination therapy

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/98

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer

Irinotecan / Vemurafenib / Cetuximab combination therapy

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/8506

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer

erlotinib / vemurafenib combination therapy

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/8507

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2135

Improved survival with MEK inhibition in BRAF-mutated melanoma

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

childhood pilocytic astrocytoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/3777

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

ovarian serous carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/3787

Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation

Pertuzumab / vemurafenib combination therapy

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

anaplastic thyroid cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5961

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

anaplastic thyroid cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6045

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

Dabrafenib / Trametinib combination therapy

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

anaplastic thyroid cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6975

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer

cetuximab / encorafenib / binimetinib combination therapy

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/7260

Interaction between cyclic adenosine monophosphate and cyclic gunaosine monophosphate in guinea pig ventricular myocardium

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

papillary thyroid cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/9018

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial

Dabrafenib / Trametinib combination therapy

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

cholangiocarcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5902

Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion

Dabrafenib / Trametinib combination therapy

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

intrahepatic cholangiocarcinoma

2 references

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5903

Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5904

Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.

Dabrafenib / Trametinib combination therapy

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/7264

A case of bronchial carcinoid with carcinoid syndrome (author transl)

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

Langerhans cell sarcoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/7583

Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study

cetuximab / encorafenib / binimetinib combination therapy

determination method

CIViC evidence level B

CIViC 5-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/7612

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

Cetuximab / encorafenib combination therapy

determination method

CIViC evidence level A

CIViC 5-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/9851

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

negative therapeutic predictor for

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/90

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/91

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

colorectal cancer

statement disputed by

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/816

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

colorectal cancer

statement disputed by

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/816

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2117

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2118

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2115

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/3827

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

positive diagnostic predictor for

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/79

Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer

papillary thyroid cancer

determination method

CIViC evidence level B

CIViC 5-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/80

Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.

hairy cell leukemia

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1127

BRAF mutations in hairy-cell leukemia

negative prognostic predictor for

papillary thyroid cancer

determination method

CIViC evidence level B

CIViC 5-star trust rating

statement disputed by

The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/102

The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/104

Prognostic value of BRAF mutations in localized cutaneous melanoma.

papillary thyroid cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

papillary thyroid cancer

determination method

CIViC evidence level B

CIViC 5-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/656

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence

colorectal cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1552

Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis

papillary thyroid cancer

determination method

CIViC evidence level B

CIViC 4-star trust rating

2 references

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2137

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

23 May 2022

https://civic.genome.wustl.edu/links/evidence/9170

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer

colorectal cancer

determination method

CIViC evidence level B

CIViC 4-star trust rating

3 references

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1940

A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC.

23 May 2022

https://civic.genome.wustl.edu/links/evidence/7156

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

23 May 2022

https://civic.genome.wustl.edu/links/evidence/7157

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

multiple myeloma

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/463

Targeting the BRAF V600E mutation in multiple myeloma

colorectal cancer

determination method

CIViC evidence level C

CIViC 2-star trust rating

statement disputed by

PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2362

PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients

pediatric low-grade glioma

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/7191

Pediatric low-grade gliomas can be molecularly stratified for risk

determination method

CIViC evidence level B

CIViC 2-star trust rating

statement disputed by

BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/82

BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy

colorectal cancer

determination method

CIViC evidence level B

CIViC 5-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/103

BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

ClinVar Variation ID

1 reference

ClinGen Allele Registry

http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA123643

14 November 2017

dbSNP Reference SNP number

152

1 reference

Ensembl transcript ID

ENST00000288602.6

1 reference

https://civic.genome.wustl.edu//links?idtype=variant&id=12

Google Knowledge Graph ID

0 references

HGVS nomenclature

NM_004333.4:c.1799T>A

2 references

ClinGen Allele Registry

http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA123643

14 November 2017

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

NC_000007.13:g.140453136A>T

2 references

ClinGen Allele Registry

http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA123643

14 November 2017

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

NP_004324.2:p.Val600Glu

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

ENST00000288602.6:c.1799T>A

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

Microsoft Academic ID

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

Sitelinks

Wikipedia(3 entries)

enwiki V600E
fawiki V600E
nowiki V600E

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q21851559&oldid=2014771929"